NASDAQ:CBLL CeriBell (CBLL) Stock Price, News & Analysis $18.43 -0.29 (-1.55%) Closing price 07/20/2026 04:00 PM EasternExtended Trading$18.80 +0.37 (+2.01%) As of 07/20/2026 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About CeriBell Stock (NASDAQ:CBLL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CeriBell alerts:Sign Up Key Stats Today's Range$18.24▼$18.8050-Day Range$16.30▼$20.0052-Week Range$10.85▼$24.33Volume231,408 shsAverage Volume376,026 shsMarket Capitalization$699.29 millionP/E RatioN/ADividend YieldN/APrice Target$22.20Consensus RatingModerate Buy Company Overview CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention. The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows. CeriBell devices typically feature automated test protocols, digital signal processing and connectivity options for integration with electronic health record systems. These diagnostic platforms are engineered to meet regulatory requirements in multiple jurisdictions and are complemented by service contracts and technical support offerings. CeriBell has developed a global presence through direct sales and distribution partnerships across North America, Europe and select international markets. By collaborating with healthcare providers, clinical laboratories and research institutions, the company focuses on refining screening protocols, delivering training resources and expanding access to early hearing assessment solutions. CeriBell’s commitment to innovation and clinical validation underpins its mission to reduce the incidence of undiagnosed hearing loss in newborns and support positive developmental outcomes in pediatric populations.AI Generated. May Contain Errors. Read More CeriBell Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks35th Percentile Overall ScoreCBLL MarketRank™: CeriBell scored higher than 35% of companies evaluated by MarketBeat, and ranked 588th out of 840 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingCeriBell has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 4 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialCeriBell has a consensus price target of $22.20, representing about 20.5% upside from its current price of $18.43.Amount of Analyst CoverageCeriBell has only been the subject of 2 research reports in the past 90 days.Read more about CeriBell's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for CeriBell are expected to grow in the coming year, from ($1.69) to ($1.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CeriBell is -11.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CeriBell is -11.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCeriBell has a P/B Ratio of 4.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about CeriBell's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.52% of the float of CeriBell has been sold short.Short Interest Ratio / Days to CoverCeriBell has a short interest ratio ("days to cover") of 4.39.Change versus previous monthShort interest in CeriBell has recently decreased by 1.81%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCeriBell does not currently pay a dividend.Dividend GrowthCeriBell does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for CeriBell this week, compared to 4 articles on an average week. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, CeriBell insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,946,191.00 in company stock.Percentage Held by Insiders20.10% of the stock of CeriBell is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsCeriBell has minimal institutional ownership at this time.Read more about CeriBell's insider trading history. Receive CBLL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CeriBell and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CBLL Stock News HeadlinesCeribell to Report Second Quarter 2026 Financial Results on August 10, 2026July 20 at 4:05 PM | globenewswire.comCeriBell (NASDAQ:CBLL) CEO Xingjuan Chao Sells 39,000 SharesJuly 10, 2026 | insidertrades.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.July 21 at 1:00 AM | Profits Run (Ad)CeriBell, Inc. (NASDAQ:CBLL) Receives Consensus Rating of "Moderate Buy" from AnalystsJuly 10, 2026 | americanbankingnews.comCeriBell (NASDAQ:CBLL) Director William Burke Sells 2,207 SharesJuly 3, 2026 | insidertrades.comInsider Selling: CeriBell (NASDAQ:CBLL) Major Shareholder Sells 202,368 SharesJuly 1, 2026 | insidertrades.comIs CeriBell, Inc. (CBLL) Among the Best Brain-Computer Interface Stocks to Buy?June 27, 2026 | insidermonkey.comIs CeriBell, Inc. (CBLL) Among the Best Brain-Computer Interface Stocks to Buy?June 27, 2026 | finance.yahoo.comSee More Headlines CBLL Stock Analysis - Frequently Asked Questions How have CBLL shares performed this year? CeriBell's stock was trading at $21.93 at the beginning of the year. Since then, CBLL stock has decreased by 16.0% and is now trading at $18.43. How were CeriBell's earnings last quarter? CeriBell, Inc. (NASDAQ:CBLL) posted its earnings results on Monday, May, 11th. The company reported ($0.52) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by $0.13. The business earned $26.49 million during the quarter, compared to analyst estimates of $26.09 million. CeriBell had a negative trailing twelve-month return on equity of 38.19% and a negative net margin of 63.51%. Read the conference call transcript. When did CeriBell IPO? CeriBell (CBLL) raised $159 million in an IPO on Friday, October 11th 2024. The company issued 10,606,060 shares at $14.00-$16.00 per share. Who are CeriBell's major shareholders? Top institutional shareholders of CeriBell include Kopp Family Office LLC (0.09%). Insiders that own company stock include Tpg Gp A, Llc, Xingjuan Chao, Josef Parvizi, Raymond Woo, Scott Blumberg, Joseph Michael Taylor, Joseph S Manni, David Foehr, William W Burke and Rebecca B Robertson. View institutional ownership trends. How do I buy shares of CeriBell? Shares of CBLL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/11/2026Today7/20/2026Next Earnings (Estimated)8/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 CBLL's financial health is in the Green zone, according to TradeSmith. CBLL has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:CBLL Previous SymbolNASDAQ:CBLL CIK1861107 WebN/A Phone(800) 436-0826FaxN/AEmployeesN/AYear Founded2014Price Target and Rating Average Price Target for CeriBell$22.20 High Price Target$30.00 Low Price Target$17.00 Potential Upside/Downside+20.5%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($1.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$53.41 million Net Margins-63.51% Pretax Margin-63.51% Return on Equity-38.19% Return on Assets-30.92% Debt Debt-to-Equity Ratio0.14 Current Ratio10.44 Quick Ratio10.01 Sales & Book Value Annual Sales$95.07 million Price / Sales7.36 Cash FlowN/A Price / Cash FlowN/A Book Value$4.19 per share Price / Book4.40Miscellaneous Outstanding Shares37,943,000Free Float30,316,000Market Cap$699.29 million OptionableN/A Beta0.77 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:CBLL) was last updated on 7/21/2026 by MarketBeat.com Staff. From Our PartnersSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredPorter flew 3,300 miles to investigate this systemPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredElon’s new "tollbooth"The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...Weiss Ratings | SponsoredElon's new "super startup"Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...Banyan Hill Publishing | Sponsored“The unseen winner of the AI race” is not SpaceXMarc Chaikin - the analyst who called Nvidia before its historic run - says a tech firm labeled 'the unseen wi...Chaikin Analytics | SponsoredBofA: Digital Dollar Coming 2025-2030Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredThey proved it worked in '76. Then buried it.In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CeriBell, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CeriBell With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
